Literature DB >> 17915832

Intellectual property policy in the pharmaceutical sciences: the effect of inappropriate patents and market exclusivity extensions on the health care system.

Aaron S Kesselheim1.   

Abstract

Though patents are effective tools for promoting innovation and protecting intellectual property in the pharmaceutical sciences, there has been growing concern about 2 important ways that patents in this field can have a negative effect on patient care and the practice of medicine. First, inventors can seek and receive patents on pharmaceutical products or research tools that stretch the statutory requirements for patenting. Second, patent holders in the pharmaceutical market can use legal loopholes or aspects of the patent registration system to extend exclusivity for inventions beyond what was anticipated by the Patent Act or subsequent legislation. The monopoly control bestowed by such inappropriate patents or manipulation of the patent system can limit options available to patients, increase the cost of health care delivery, and make cooperative research more difficult. In response, several different government and market-based efforts have emerged to promote more equitable patent policy in health care that encourages dissemination of ideas while still supporting the development of innovative products.

Entities:  

Mesh:

Year:  2007        PMID: 17915832      PMCID: PMC2751478          DOI: 10.1208/aapsj0903033

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  8 in total

1.  University-based science and biotechnology products: defining the boundaries of intellectual property.

Authors:  Aaron S Kesselheim; Jerry Avorn
Journal:  JAMA       Date:  2005-02-16       Impact factor: 56.272

2.  Oxymoron no more: the potential of nonprofit drug companies to deliver on the promise of medicines for the developing world.

Authors:  Victoria G Hale; Katherine Woo; Helene Levens Lipton
Journal:  Health Aff (Millwood)       Date:  2005 Jul-Aug       Impact factor: 6.301

3.  Universities urged to do more for poor nations.

Authors:  Erika Check
Journal:  Nature       Date:  2006-11-23       Impact factor: 49.962

4.  Biomedical patents and the public's health: is there a role for eminent domain?

Authors:  Aaron S Kesselheim; Jerry Avorn
Journal:  JAMA       Date:  2006-01-25       Impact factor: 56.272

5.  Delaying generic competition--corporate payoffs and the future of Plavix.

Authors:  Miriam Shuchman
Journal:  N Engl J Med       Date:  2006-09-28       Impact factor: 91.245

6.  Medical-process patents--monopolizing the delivery of health care.

Authors:  Aaron S Kesselheim; Michelle M Mello
Journal:  N Engl J Med       Date:  2006-11-09       Impact factor: 91.245

7.  Extensions of intellectual property rights and delayed adoption of generic drugs: effects on medicaid spending.

Authors:  Aaron S Kesselheim; Michael A Fischer; Jerry Avorn
Journal:  Health Aff (Millwood)       Date:  2006 Nov-Dec       Impact factor: 6.301

Review 8.  Can patents deter innovation? The anticommons in biomedical research.

Authors:  M A Heller; R S Eisenberg
Journal:  Science       Date:  1998-05-01       Impact factor: 47.728

  8 in total
  4 in total

1.  Improving regulatory capacity to manage risks associated with trade agreements.

Authors:  Helen L Walls; Richard D Smith; Peter Drahos
Journal:  Global Health       Date:  2015-03-21       Impact factor: 4.185

2.  Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals.

Authors:  Jing Hao; Rosa Rodriguez-Monguio; Enrique Seoane-Vazquez
Journal:  PLoS One       Date:  2015-10-15       Impact factor: 3.240

3.  The role of intellectual property rights on access to medicines in the WHO African region: 25 years after the TRIPS agreement.

Authors:  Marion Motari; Jean-Baptiste Nikiema; Ossy M J Kasilo; Stanislav Kniazkov; Andre Loua; Aissatou Sougou; Prosper Tumusiime
Journal:  BMC Public Health       Date:  2021-03-11       Impact factor: 3.295

4.  Rising health care costs and life-cycle management in the pharmaceutical market.

Authors:  Aaron S Kesselheim
Journal:  PLoS Med       Date:  2013-06-04       Impact factor: 11.069

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.